c-Kit Mutation Detection Kit
No. of Reactions*
|c-Kit Mutation Detection Kit for Real-Time PCR||
*Includes all controls.
c-Kit Mutations in Melanoma
KIT mutations are found in approximately five to 30 percent of acral and mucosal melanomas and melanomas arising on chronically sun-damaged skin. Mutations occur primarily in exon 11 and secondarily in exons 13, 17, and 18. The overall response rate to imatinib in KIT-mutated melanoma is 16 to 23 percent, demonstrating the value of KIT-mutation testing in melanoma patients. 
The c-Kit Mutation Detection Kit detects the following mutations:
Testing Procedure and Analysis
EntroGen’s c-Kit Mutation Detection Kit is a polymerase chain reaction (PCR)-based assay that uses allele-specific primers to identify the presence of somatic mutations in c-KIT genes. The testing procedure involves three (3) simple steps:
- Isolation of DNA from tumor biopsies, paraffin-embedded sections (FFPE), or fine needle aspirates (FNA)
- Amplification of regions of the c-KIT genes using allele-specific primers
- Analysis of the captured amplification data.
This test can be completed in approximately 2 hours from isolation of DNA to test result.
Equipment and Materials
EntroGen’s c-Kit Mutation Detection Kit requires a real-time PCR instrument capable of detecting FAM, VIC, ROX and CY5 fluorescent probes.
This test includes reagents required for the PCR amplification/detection, as well as validated reaction controls. Columns and reagents for DNA isolation are not included.
EntroGen’s Thyroid Cancer Mutation Panel is provided for research use only (RUO). Not for use in diagnostic procedures.
 Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-3190.
 Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-2334.
 Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-2909.